JERUSALEM, July 2, 2012 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN) is pleased to announce that it has received CE Mark enabling commercialization of its Deep TMS system to treat neuropathic chronic pain (“neuropathic pain”) in the European Union and the countries in Asia and Latin America that recognize the CE Mark.

“Neuropathic pain is the sixth indication for which Deep TMS has achieved CE Mark approval,” commented Uzi Sofer, Brainsway’s CEO. “Previous CE Marks were for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson’s diseases and post-traumatic stress disorder. As our therapeutic pipeline continues to expand, it is very exciting to continue to bring proven new Deep TMS treatments to market.”